Literature DB >> 12598444

CNV subtype in first eyes predicts severity of ARM in fellow eyes.

S Abugreen1, K A Muldrew, M R Stevenson, R VanLeeuwen, P T V M DeJong, U Chakravarthy.   

Abstract

AIM: To examine the relation between the type of choroidal neovascularisation (CNV) in the first eye and age related maculopathy (ARM) severity in the fellow eye.
METHODS: Colour fundus photographs and fluorescein angiograms from 67 subjects with a clinical diagnosis of CNV in one eye were scrutinised. CNV was classified as wholly classic, predominantly classic, minimally classic, or occult based on the proportion of classic leakage within the lesion. ARM changes in the fellow eye were assigned a severity stage using the system described by the Rotterdam Eye Study. Logistic regression analysis was employed to examine the association between CNV subtype and ARM stage.
RESULTS: Of subjects with classic or predominantly classic CNV in the first eye 78% exhibited least no or early ARM features in the fellow eye. By contrast, 85% of subjects with minimally classic or occult CNV in the first eye exhibited more advanced ARM features in the fellow eye. Kruskall-Wallis one way ANOVA by ranks showed that this was highly significant (p = 0.002). Logistic regression analysis showed that as the proportion of occult CNV increased in the first eye, fellow eyes of subjects in this category were more likely to have been assigned to a higher ARM stage (p = 0.019). The area occupied by the CNV in the first eye also influenced severity of ARM changes in the fellow eye.
CONCLUSION: The type and extent of CNV in the first affected eye has a distinct relation to ARM severity in the fellow eye. Fellow eyes of subjects with minimally classic or occult CNV in the first affected eye show widespread ARM changes suggestive of retinal pigment epithelial dysfunction. These findings suggest that classic CNV may be focal disease while occult CNV is essentially a more widespread retinal pigment epithelial disorder.

Entities:  

Mesh:

Year:  2003        PMID: 12598444      PMCID: PMC1771546          DOI: 10.1136/bjo.87.3.307

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  23 in total

Review 1.  Age-related macular degeneration and risk factors for the development of choroidal neovascularization in the fellow eye.

Authors:  D J Pieramici; S B Bressler
Journal:  Curr Opin Ophthalmol       Date:  1998-06       Impact factor: 3.761

2.  Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Macular Photocoagulation Study Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1997-06

3.  Council Lecture. Drusen and their relationship to senile macular degeneration.

Authors:  S H Sarks
Journal:  Aust J Ophthalmol       Date:  1980-05

4.  Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1999-10

5.  Incidence and progression rates of age-related maculopathy: the Rotterdam Study.

Authors:  C C Klaver; J J Assink; R van Leeuwen; R C Wolfs; J R Vingerling; T Stijnen; A Hofman; P T de Jong
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-09       Impact factor: 4.799

6.  The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study.

Authors:  R Klein; B E Klein; S C Jensen; S M Meuer
Journal:  Ophthalmology       Date:  1997-01       Impact factor: 12.079

7.  Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2.

Authors: 
Journal:  Am J Ophthalmol       Date:  2001-05       Impact factor: 5.258

Review 8.  Drusen in age-related macular degeneration: pathogenesis, natural course, and laser photocoagulation-induced regression.

Authors:  A Abdelsalam; L Del Priore; M A Zarbin
Journal:  Surv Ophthalmol       Date:  1999 Jul-Aug       Impact factor: 6.048

9.  Argon laser photocoagulation for senile macular degeneration. Results of a randomized clinical trial.

Authors: 
Journal:  Arch Ophthalmol       Date:  1982-06

10.  Senile disciform macular degeneration in the second eye.

Authors:  Z Gregor; A C Bird; I H Chisholm
Journal:  Br J Ophthalmol       Date:  1977-02       Impact factor: 4.638

View more
  8 in total

1.  CNV subtype in first eyes predicts severity of ARM in fellow eyes.

Authors:  L Tong
Journal:  Br J Ophthalmol       Date:  2004-01       Impact factor: 4.638

2.  Prognosis of untreated occult choroidal neovascularization.

Authors:  Ilse Krebs; Ulrike Stolba; Carl Glittenberg; Orang Seyeddain; Thomas Benesch; Susanne Binder
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-10-27       Impact factor: 3.117

3.  Changes in macular drusen parameters preceding the development of neovascular age-related macular degeneration.

Authors:  Ali Lamin; Adam M Dubis; Sobha Sivaprasad
Journal:  Eye (Lond)       Date:  2019-01-24       Impact factor: 3.775

Review 4.  Genetic predictors of response to photodynamictherapy.

Authors:  Francesco Parmeggiani; Donato Gemmati; Ciro Costagliola; Francesco Semeraro; Paolo Perri; Sergio D'Angelo; Mario R Romano; Katia De Nadai; Adolfo Sebastiani; Carlo Incorvaia
Journal:  Mol Diagn Ther       Date:  2011-08-01       Impact factor: 4.074

Review 5.  Age-related macular degeneration--emerging pathogenetic and therapeutic concepts.

Authors:  Karen M Gehrs; Don H Anderson; Lincoln V Johnson; Gregory S Hageman
Journal:  Ann Med       Date:  2006       Impact factor: 4.709

6.  Treatment of age-related macular degeneration: focus on ranibizumab.

Authors:  Martin S Spitzer; Focke Ziemssen; Karl U Bartz-Schmidt; Faik Gelisken; Peter Szurman
Journal:  Clin Ophthalmol       Date:  2008-03

7.  Different Outcomes of Anti-VEGF Treatment for Neovascular AMD according to Neovascular Sutypes and Baseline Features: 2-Year Real-Life Clinical Outcomes.

Authors:  Alessandro Arrigo; Andrea Saladino; Emanuela Aragona; Stefano Mercuri; Ugo Introini; Francesco Bandello; Maurizio Battaglia Parodi
Journal:  Biomed Res Int       Date:  2021-05-24       Impact factor: 3.411

8.  Drusen characteristics of type 2 macular neovascularization in age-related macular degeneration.

Authors:  Daniel Ahmed; Martin Stattin; Anna-Maria Haas; Alexandra Graf; Katharina Krepler; Siamak Ansari-Shahrezaei
Journal:  BMC Ophthalmol       Date:  2020-09-25       Impact factor: 2.209

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.